So far in 2020, $26.5 billion has been invested in global fintech companies. That amounts to 14 percent of all investment dollars.
COVID-19
Armed with new funding, Omio is poised for organic growth and potential M&A activities with similar businesses that may be struggling in the current...
This year is easily on track to post the highest biotech IPO numbers in five years, both in terms of number and size of offerings.
Two Greycroft executives discuss why they've continued to invest throughout the global pandemic, and what has changed in today's startup environment.
ANA Therapeutics is now one of the first companies to have its COVID-19 treatment go into human clinical trials.
ExeVir Bio is harnessing a llama-derived antibody technology platform to generate robust antiviral therapies against coronaviruses.
South Korea has attracted entrepreneurs from around the world who are eager to grow their businesses during the pandemic.
In the first half of 2020, investors globally put $16.55 billion to work in biotech and life science sectors.
This latest investment brings the total raised to £65 million, and will be used to consolidate the company’s market share in the U.K. and to fund its...
Venture investment in Latin America is more than doubling every year. The region is turning to startups to help overcome the impact of COVID-19.
In a mid-year check-in on unicorn status, we find that software services and online education have grown as new unicorn candidates while fintech and...
24.5K Followers